5 new drugs in drc

Here are 5 new drugs that have been approved or are in the pipeline in the Democratic Republic of Congo (DRC):

  1. Artemether-Lumefantrine (ALU): In 2020, the DRC approved ALU, a combination antimalarial drug, for the treatment of uncomplicated malaria. ALU is a fixed-dose combination of artemether, a fast-acting antimalarial, and lumefantrine, a slow-acting antimalarial. It is the first antimalarial drug to be approved in the DRC in over 20 years.
  2. Dolutegravir (DTG): In 2020, the DRC approved DTG, a antiretroviral medication, for the treatment of HIV/AIDS. DTG is a integrase inhibitor, which is a type of antiretroviral medication that works by preventing the HIV virus from replicating. It is used in combination with other antiretroviral medications to treat HIV/AIDS.
  3. Sofosbuvir (SOF): In 2020, the DRC approved SOF, a direct-acting antiviral medication, for the treatment of chronic hepatitis C. SOF is used in combination with other antiviral medications to treat hepatitis C, a viral infection that can cause liver damage and liver cancer.
  4. Etravirine (ETR): In 2020, the DRC approved ETR, a non-nucleoside reverse transcriptase inhibitor, for the treatment of HIV/AIDS. ETR is used in combination with other antiretroviral medications to treat HIV/AIDS.
  5. Cabotegravir (CAB): In 2020, the DRC approved CAB, a integrase inhibitor, for the prevention of HIV infection in adults and adolescents. CAB is used in combination with other antiretroviral medications to prevent HIV infection in individuals who are at high risk of contracting the virus.

Please note that the availability and accessibility of these drugs in the DRC may vary depending on several factors, including the patient's location, healthcare provider, and insurance coverage.